Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study

Parkinson plus diseases, comprising mainly progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) are rare neurodegenerative conditions. We designed a double-blind randomized placebo-controlled trial of riluzole as a potential disease-modifying agent in Parkinson plus disorders (NNIP...

Full description

Saved in:
Bibliographic Details
Main Authors: Bensimon, Gilbert, Ludolph, Albert, Agid, Yves, Vidailhet, Marie, Payan, Christine, Leigh, P. Nigel
Format: Artigo
Language:Inglês
Published: Oxford University Press 2009
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2638696/
https://ncbi.nlm.nih.gov/pubmed/19029129
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/brain/awn291
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items